公开(公告)号：US20220023306A1

公开(公告)日：2022-01-27

申请号：US17428094

申请日：2020-02-03

Applicant: Reneo Pharmaceuticals, Inc.

Inventor： Colin O'CARROLL ,  Niall O'DONNELL ,  Lynn PURKINS ,  Alex DORENBAUM

IPC: A61K31/5375 ,  A61K31/415 ,  A61K31/192 ,  A61P3/00 ,  A61K31/09 ,  A61K31/455 ,  A61K31/525 ,  A61K31/197 ,  A61K31/4188 ,  A61K31/51 ,  A61K31/4415 ,  A61K31/385 ,  A61K31/19 ,  A61K31/225 ,  A61K33/30 ,  A61K31/122 ,  A61K31/355 ,  A61K31/375 ,  A61K31/714 ,  A61K31/519 ,  G01N33/497

Abstract: Described herein is the use of PPARδ agonists in the treatment of fatty acid oxidation disorders.

公开(公告)号：US11931365B2

公开(公告)日：2024-03-19

申请号：US18101527

申请日：2023-01-25

Applicant: Reneo Pharmaceuticals, Inc.

Inventor： Niall O′Donnell ,  Lynn Purkins ,  Alejandro Dorenbaum

IPC: A61K31/5375 ,  A61K45/06 ,  A61P21/00

CPC classification number: A61K31/5375 ,  A61K45/06 ,  A61P21/00

Abstract: Described herein is the use sodium (E)-2-(4-((3-(4-fluorophenyl)-3-(4-(3-morpholinoprop-1-yn-1-yl)phenyl)allyl)oxy)-2-methylphenoxy)acetate in the preparation of pharmaceutical compositions for the treatment of diseases or conditions that would benefit by administration with a PPARδ agonist compound.

公开(公告)号：US20230233570A1

公开(公告)日：2023-07-27

申请号：US18101527

申请日：2023-01-25

Applicant: Reneo Pharmaceuticals, Inc.

Inventor： Niall O'DONNELL ,  Lynn PURKINS ,  Alejandro DORENBAUM

IPC: A61K31/5375 ,  A61K45/06 ,  A61P21/00

CPC classification number: A61K31/5375 ,  A61K45/06 ,  A61P21/00

Abstract: Described herein is the use sodium (E)-2-(4-((3-(4-fluorophenyl)-3-(4-(3-morpholinoprop-1-yn-1-yl)phenyl)allyl)oxy)-2-methylphenoxy)acetate in the preparation of pharmaceutical compositions for the treatment of diseases or conditions that would benefit by administration with a PPARδ agonist compound.

公开(公告)号：US20220135532A1

公开(公告)日：2022-05-05

申请号：US17572037

申请日：2022-01-10

Applicant: Reneo Pharmaceuticals, Inc.

Inventor： Susana DEL RIO GANCEDO ,  Osama SULEIMAN ,  Emma SHARP ,  Cristina BALOGH ,  Rachael LEE ,  Julie MACRAE ,  Neil FEEDER

IPC: C07D295/096 ,  A61K9/00 ,  A61K9/08 ,  A61K9/20 ,  A61K9/48

Abstract: Described herein is crystalline sodium (E)-2-(4-((3-(4-fluorophenyl)-3-(4-(3-morpholinoprop-1-yn-1-yl)phenyl)allyl)oxy)-2-methylphenoxy)acetate, uses of such crystalline material in the preparation of pharmaceutical compositions for the treatment of diseases or conditions that would benefit by administration with a PPARδ agonist compound.

公开(公告)号：US20240016809A1

公开(公告)日：2024-01-18

申请号：US18470330

申请日：2023-09-19

Applicant: Reneo Pharmaceuticals, Inc.

Inventor： Niall O'DONNELL ,  Lynn PURKINS ,  Alejandro DORENBAUM

IPC: A61K31/5375 ,  A61P21/00 ,  A61K45/06

CPC classification number: A61K31/5375 ,  A61P21/00 ,  A61K45/06

Abstract: Described herein is the use sodium (E)-2-(4-((3-(4-fluorophenyl)-3-(4-(3-morpholinoprop-1-yn-1-yl)phenyl)allyl)oxy)-2-methylphenoxy)acetate in the preparation of pharmaceutical compositions for the treatment of diseases or conditions that would benefit by administration with a PPARδ agonist compound.

公开(公告)号：US20220370467A1

公开(公告)日：2022-11-24

申请号：US17761515

申请日：2020-09-18

Applicant: Reneo Pharmaceuticals, Inc. ,  WASHINGTON UNIVERSITY

Inventor： Colin O'CARROLL ,  Niall O'DONNELL ,  Jeffrey MINER

IPC: A61K31/5375 ,  A61P13/12 ,  A61K31/192 ,  A61K45/06

Abstract: Described herein is the use of a PPAR-delta agonist in the treatment of kidney diseases, wherein: the kidney disease is Alport syndrome, Goodpasture syndrome, thin basement membrane nephropathy (TBMN), focal segmental glomerulosclerosis (FSGS), benign familial hematuria (BFH), post-transplant anti-GBM (Glomerular Basement Membrane) nephritis, X-linked Alport syndrome (XLAS), autosomal recessive Alport syndrome (ARAS) or autosomal dominant Alport syndrome (ADAS).

公开(公告)号：US11267795B2

公开(公告)日：2022-03-08

申请号：US17381005

申请日：2021-07-20

Applicant: Reneo Pharmaceuticals, Inc.

Inventor： Susana Del Rio Gancedo ,  Osama Suleiman ,  Emma Sharp ,  Cristina Balogh ,  Rachael Lee ,  Julie Macrae ,  Neil Feeder

IPC: A61K9/08 ,  C07D295/096 ,  A61K9/00 ,  A61K9/20 ,  A61K9/48

Abstract: Described herein is crystalline sodium (E)-2-(4-((3-(4-fluorophenyl)-3-(4-(3-morpholinoprop-1-yn-1-yl)phenyl)allyl)oxy)-2-methylphenoxy)acetate, uses of such crystalline material in the preparation of pharmaceutical compositions for the treatment of diseases or conditions that would benefit by administration with a PPARδ agonist compound.

公开(公告)号：US20220024888A1

公开(公告)日：2022-01-27

申请号：US17381005

申请日：2021-07-20

Applicant: Reneo Pharmaceuticals, Inc.

Inventor： Susana DEL RIO GANCEDO ,  Osama SULEIMAN ,  Emma SHARP ,  Cristina BALOGH ,  Rachael LEE ,  Julie MACRAE ,  Neil FEEDER

IPC: C07D295/096 ,  A61K9/00 ,  A61K9/08 ,  A61K9/20 ,  A61K9/48

Abstract: Described herein is crystalline sodium (E)-2-(4-((3-(4-fluorophenyl)-3-(4-(3-morpholinoprop-1-yn-1-yl)phenyl)allyl)oxy)-2-methylphenoxy)acetate, uses of such crystalline material in the preparation of pharmaceutical compositions for the treatment of diseases or conditions that would benefit by administration with a PPARδ agonist compound.

公开(公告)号：US20240002356A1

公开(公告)日：2024-01-04

申请号：US18333454

申请日：2023-06-12

Applicant: Reneo Pharmaceuticals, Inc.

Inventor： Susana DEL RIO GANCEDO ,  Osama SULEIMAN ,  Emma SHARP ,  Cristina BALOGH ,  Rachael LEE ,  Julie MACRAE ,  Neil FEEDER

IPC: C07D295/096 ,  A61K9/00 ,  A61K9/08 ,  A61K9/20 ,  A61K9/48

CPC classification number: C07D295/096 ,  A61K9/0019 ,  A61K9/08 ,  A61K9/2054 ,  A61K9/4825 ,  A61K9/4866 ,  A61K9/0053 ,  C07B2200/13

Abstract: Described herein is crystalline sodium (E)-2-(4-((3-(4-fluorophenyl)-3-(4-(3-morpholinoprop-1-yn-1-yl)phenyl)allyl)oxy)-2-methylphenoxy)acetate, uses of such crystalline material in the preparation of pharmaceutical compositions for the treatment of diseases or conditions that would benefit by administration with a PPARS agonist compound.

公开(公告)号：US20230416210A1

公开(公告)日：2023-12-28

申请号：US18253023

申请日：2021-11-19

Applicant: Reneo Pharmaceuticals, Inc.

Inventor： Michael Trevelyan WILLIAMS

IPC: C07D265/30 ,  B01J23/44

CPC classification number: C07D265/30 ,  B01J23/44

Abstract: Described herein are methods of making the PPARδ agonist compound (E)-2-(4-((3-(4-fluorophenyl)-3-(4-(3-morpholinoprop-1-yn-1-yl)phenyl)allyl)oxy)-2-methylphenoxy)acetic acid, including salt forms thereof.